Document is current
Any future updates will be listed below
-
Authors
Cracknell Daniels, Bethan https://orcid.org/0000-0002-3707-5706
Endy, Timothy
Lewnard, Joseph https://orcid.org/0000-0002-5417-8475
Di Fabio, Jose Luis https://orcid.org/0000-0002-1187-7110
Cortes-Azuero, Oscar
Breugelmans, J. Gabrielle https://orcid.org/0000-0001-8015-3717
Cauchemez, Simon https://orcid.org/0000-0001-9186-4549
Precioso, Alexander
Ko, Albert https://orcid.org/0000-0001-9023-2339
Chandler, Rebecca E.
Thomas, Stephen J. https://orcid.org/0000-0002-8368-7682
Lurie, Nicole
Salje, Henrik https://orcid.org/0000-0003-3626-4254
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 20 November 2025
First Online: 15 January 2026
Competing interests
: H.S. and O.C.-A. are consultants for Valneva regarding phase IV trial design. H.S. has been a consultant for Gavi Alliance. H.S. and B.C.D. are consultants for CEPI. T.E., J.L.d.F., J.G.B., A.P., R.E.C. and N.L. are paid employees of CEPI. CEPI has supported the technology transfer of IXCHIQ to Institut Butantan in Brazil. The other authors declare no competing interests.
